We performed bacteriological and clinical studies on NM441, a new quinolone antibiotic, with the following results. The antibacterial activities of NM394 against clinical isolates (10 species, 242 strains) were compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The MIC 90s of NM394 against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter freundii, Proteus vulgaris, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aeruginosa were 1.56, > 100, 50, ≤0.05, ≤0.05, ≤0.05, 0.10, 0.10, 0.10, 0.20 and 1.56μg/ml, respectively. The activities of NM394 against gram positive bacteria were less potent than those of TFLX, but almost as potent as OFLX and CPFX. The activities against gram negative bacteria were almost as potent as those of CPFX, and more potent than those of OFLX and TFLX. In particular, NM394 showed a high antibacterial activity against P. aeruginosa. NM441 was administered to a total of 22 patients, 20 cases with respiratory tract infections and 2 urinary tract infections, at a daily dose of 200~400mg for 2~21days. Clinical response was excellent in 5 cases, good in 15 and fair in 2. Side effects were observed in a total of 3 cases (13.6%), insomnia in 1, nausea · vomiting in 1 and rash in 1. Abnormal laboratory findings were observed in a total of 3 cases (13.6%), elevations of S-GOT·S-GPT·γ-GTP, S-GOT and S- GOT·S-GPT each in 1 case.
|Number of pages||6|
|Journal||Japanese Journal of Chemotherapy|
|Issue number||SUPPL. 1|
|Publication status||Published - May 7 1996|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)